|
|
||||||||
1 Laboratoire de Pharmacologie Cardiovasculaire, EA 3116, Faculté de Pharmacie, UHP-Nancy 1, 54001 Nancy Cedex; 2 Institut de Recherches Internationales Servier, 92415 Courbevoie Cedex, France
| |
ABSTRACT |
|---|
|
|
|---|
Because little is known of the
intracellular mechanisms involved in the vasoconstrictor effect of
melatonin (Mel), we examined the in vitro effects of Mel by using
perfused cylindrical segments of the rat tail artery loaded with the
intracellular Ca2+ concentration
([Ca2+]i)-sensitive fluorescent dye, fura 2. Mel (10
14 to 10
4 M) had no effect on
baseline perfusion pressure or [Ca2+]i but
increased, at submicromolar concentrations, the vasoconstrictor effect
of norepinephrine (NE) (P = 0.0029). Mel did not modify NE-induced [Ca2+]i mobilization, and thus the
[Ca2+]i sensitivity of NE-induced contraction
increased in the presence of Mel. Mel consistently increased
KCl-induced vasoconstriction and [Ca2+]i
sensitivity of contraction, but differences were not statistically significant. In conclusion, Mel increases the
[Ca2+]i sensitivity of vasoconstriction
evoked by NE suggesting that Mel may amplify endogenous vasoconstrictor
responses to sympathetic outflow.
tail artery; intracellular calcium; norepinephrine
| |
INTRODUCTION |
|---|
|
|
|---|
MELATONIN (Mel) produces vasodilatation (6) or vasoconstriction (4, 17), or has no effect (1) in vivo. Some in vitro experiments show vasodilatation at micromolar concentration (21-23, 25), whereas others show vasoconstriction at nanomolar concentrations (7, 8, 10, 14, 15, 29).
A primary vasoconstrictor effect at nanomolar concentration would be in agreement with its cerebrovascular constrictor effect in vivo. However, a direct vasoconstrictor effect of Mel is difficult to obtain in vitro (8). Ting et al. (26) suggested that Mel constricts pressurized, cylindrical segments but not arterial rings. We tested whether Mel vasoconstricts perfused, pressurized cylindrical segments of the rat tail artery.
A second aspect of our study involved the intracellular
transduction mechanism by which Mel potentiates vasoconstriction. Whereas some reports suggest that the effect of Mel involves
intracellular Ca2+ concentration
([Ca2+]i), others suggest that the effect may
be independent of changes in [Ca2+]i.
Regarding the first hypothesis Weekley (31) suggested that Mel constricted the pig coronary artery (preconstricted with KCl) by
releasing norepinephrine (NE) from perivascular nerves because this
effect was abolished by prior treatment with 6-hydroxydopamine, which
destroys the structure of sympathetic nerve terminals. NE released by
Mel would then stimulate a postsynaptic
1-adrenoceptor and produce an increase in [Ca2+]i.
Further evidence suggesting an involvement of
[Ca2+]i was provided by Geary et al.
(10). They showed that Mel reduced the diameter of
pressurized rat cerebral arteries and this effect was abolished by the
G protein inhibitor, pertussis toxin, and was attenuated by bradykinin
calcium channel blockers. They suggested Mel acts via a Gi
or Go protein-coupled receptor and activation of the latter
leads to inhibition of the large conductance of Ca2+-activated K+ channels that regulates
membrane potential and thus Ca2+ entry.
Other experiments suggest that changes in [Ca2+]i may not be necessary. Krause et al. (14) showed Mel potentiated the vasoconstrictor response of the rat tail artery to NE and suggested this could be explained by a postsynaptic mechanism by which Mel lowers production of the vasodilator cAMP. The latter effect, reported by Capsoni et al. (5), provided evidence that nanomolar concentration of Mel inhibits forskolin-stimulated cAMP in rat circle of Willis arteries.
One way of resolving the above problem is to measure vasomotion and [Ca2+]i simultaneously in the same preparation. In our paper, therefore, Mel-induced changes in the [Ca2+]i sensitivity of vasoconstriction were evaluated in segments of the rat tail artery loaded with the [Ca2+]i-sensitive dye, fura 2.
A final aspect of our study is the use of high KCl and NE as vasoconstrictor agents. Several authors (12) have shown that electromechanical stimulation with high KCl involves low [Ca2+]i sensitivity of contraction, whereas the latter is amplified in pharmacomechanical stimulation with NE. Furthermore, we have shown that NE-induced vasoconstriction of the rat tail artery has a substantial [Ca2+]i-independent component (20). Were Mel to act on the latter, then it could be expected that Mel would potentiate NE-induced, but not KCl-induced, changes in [Ca2+]i sensitivity of contraction.
| |
METHODS |
|---|
|
|
|---|
The tail arteries of male Wistar rats (8-9 mo, 544 ± 17 g, Iffa Credo, L'Arbresle, France) were dissected between 9 and 10 AM [nadir of the Mel cycle (18)] and experiments performed between 10 AM and 2 PM. The technique for measurement of vasoconstriction and [Ca2+]i mobilization has been previously described (2, 3, 20, 27). Cannulated segments of the tail artery were perfused with a physiological salt solution (PSS) (mM: 140 NaCl, 5 KCl, 1.5 CaCl2, 1 MgCl2, 6 glucose, and 10 HEPES; in 100% O2; 7.40 ± 0.01 pH; 37°C; at a rate of 1.5 ml/min) and placed in a spectrofluorometer cuvette (Fluorolog F1 T11, SPEX, Edison, NJ). The endothelium was removed by brief coperfusion of air (27).
Baseline perfusion pressure (mmHg) and tissue autofluorescence (AF)
(excitation 360 nm, emission 510 nm) were measured, and the arterial
segment was perfused with a high K+ solution (80 mM KCl, 2 min, 3×) followed by NE (10
6 M, 2 min). Segments whose
vasoconstrictor responses to KCl or NE were <30 or >50 mmHg were
discarded (6/48 = 10%). This initial vasoconstrictor
response to KCl (80 mM) was used to normalize subsequent
vasoconstrictor responses. Fura 2 was loaded by perfusing PSS
containing fura 2-acetoxymethyl (AM) ester (5 × 10
6 M) for 90 min, followed by washout with PSS (20 min);
isoemissive fluorescence was measured before and after fura 2 loading
to calculate loading efficiency.
Excitation (300 to 400 nm, emission 510 nm) and emission fluorescence
spectra (480 to 530 nm, excitation 340 or 380 nm) and absorption (340, 380, and 510 nm) of Mel [10
10 to 10
4 M in
1% vol/vol ethanol, n = 4] were determined. Mel
fluorescence was undetectable at concentrations <10
4 M. At 10
4 M fluorescence was 10 times less than that
of the fura 2-loaded segment. Absorption was insignificantly low
(<0.02).
Segments were illuminated alternatively (1 s) at excitation wavelengths
of 340 and 380 nm (emission 510 nm). Background-corrected (see below)
changes in fluorescence at 340 nm were divided by those at 380 nm
(R'340/380). The formula of
Grynkiewicz et al. (11) as modified by Scanlon et al.
(24), is often used to calculate
[Ca2+]i (in nM)
|
5 M, 5 min);
R'min is the fluorescence ratio in calcium-free PSS containing EGTA (10
2 M) and ionomycin (10
5
M, 7 min);
' was the ratio of F'380 at 0 and
saturating calcium concentration. The ratio of R'max
over R'min was used as an indication of the extent
of hydrolysis of the fura 2-AM ester in each group. Background
fluorescence was measured following perfusion with MnCl2
(10
3 M) and ionomycin (10
5 M) for 3 min.
The Kd for fura 2 may be higher than 224 nM in
smooth muscle cytoplasm (13). For instance,
Kd can be increased by as much as 300% by
adding proteins to the calibration solutions (28). Therefore, we used the simpler formula to estimate
[Ca2+]i [in arbitrary units (a.u.)]
|
In a first experiment, arteries were stimulated six times with NE
(10
6 M, 2 min, 5 min washout between each stimulation) in
the presence or absence of increasing concentrations of Mel
(10
14 to 10
4 M). Time and fura 2 controls
followed the same protocol in the absence of Mel but were loaded
(n = 6) or not loaded (n = 6) with fura 2. Fura 2 had no effect on the vasoconstrictor response to NE (results not shown).
In a second experiment, noncumulative dose-response curves to KCl (20 to 120 mM) and NE (10
7 to 3 × 10
5 M) were
performed in the presence or absence of Mel (10
7 M). In
this second experiment dose-response curves to KCl and NE were
performed on the same segment and were randomized.
All chemicals were purchased from Sigma Chemical (St. Louis, MO), Calbiochem (San Diego, CA), or Merck (Darmstadt, Germany). Mel was dissolved in ethanol (100%) then diluted with PSS (final ethanol concentration, 1% vol/vol).
Results are expressed as means ± SE. Vasoconstrictor (
P) and change
in [Ca2+]i
(
[Ca2+]i) responses were presented as
differences between baseline pressure and
[Ca2+]i. Differences between means were
determined by ANOVA followed by the Bonferroni test. The null
hypothesis was rejected at P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
A baseline perfusion pressure of 18 ± 1 mmHg was
stable throughout the experiment. Neither ethanol nor Mel had any
effect on baseline perfusion pressure (P > 0.05 for
both, Fig. 1). Mel potentiated NE-induced
(10
6 M) contraction in a bell-shaped fashion (Fig.
2A). Mel had no effect on
NE-evoked [Ca2+]i mobilization (for example,
[Ca2+]i were +0.25 ± 0.02 and
+0.26 ± 0.04 a.u. in the absence and presence of
10
6 M Mel, P = 0.6427). Mel also
increased the [Ca2+]i sensitivity of
vasoconstriction in a bell-shaped fashion (Fig. 2B).
|
|
NE induced a monophasic increase in perfusion pressure and a
biphasic increase in [Ca2+]i, whereas KCl
induced a monophasic increase in
[Ca2+]i (Figs.
3 and 4).
Initial vasoconstrictor responses to KCl (
P, 80 mM) were +67 ± 9 and +61 ± 4 mmHg in the presence or absence of Mel,
respectively. Mel (10
7 M) had no significant effect on
KCl-induced vasoconstriction (Figs. 3 and
5). Taking, for example, an increase in
perfusion pressure of +80 mmHg (produced by 100 mM KCl or 3 × 10
5 M NE, see Fig. 5) Mel had a slight, nonsignificant
effect in the presence of KCl but increased the response to NE by 76%.
Mel induced a similar increase in the vasoconstrictor responses to all
concentrations of NE
10
6 M. Mel had no effect on the
vasoconstrictor response to NE at 3 × 10
7 M [27 ± 7 to 32 ± 7% KCl (80 mM)] but potentiated (a 110% increase) vasoconstrictor response to 10
6 M NE [51 ± 10 to
106 ± 19% KCl (80 mM)]. Mel had no effect on NE-induced
[Ca2+]i mobilization (Figs.
3-5). Thus Mel increased [Ca2+]i
sensitivity of NE-induced vasoconstriction. Taking, for example, a
value of
[Ca2+]i (a.u.) of +0.4, using the
data presented in Fig. 5, calculated increases in perfusion pressure
(
P in mmHg) were 49 ± 15 and 23 ± 13 mmHg
(P > 0.05) for KCl, and 134 ± 20 and 71 ± 13 mmHg (P < 0.05) for NE, in the presence and absence
of Mel (10
7 M). Maximal fluorescence in the presence of
KCl (R'340/380= 2.40 ± 0.13) or NE
(R'340/380 = 1.87 ± 0.15) was far less than
that produced by ionomycin (R'max = 6.21 ± 0.37).
|
|
|
| |
DISCUSSION |
|---|
|
|
|---|
Mel has no effect on baseline or KCl-induced increases in
perfusion pressure of the rat tail artery but potentiates
vasoconstriction induced by NE. The lack of effect of Mel on baseline
perfusion pressure, in our experiment, suggests there may be some
threshold pressure below which Mel does not increase perfusion
pressure, because Ting et al. (26) showed that Mel
decreases lumen diameter in pressurized (60 mmHg) rat tail artery
segments. Furthermore, in our experiment, Mel had no effect on the
vasoconstrictor response to NE at 3 × 10
7 M but
potentiated that to 10
6 M NE.
Although, there is a consistent effect of Mel on KCl-induced
vasoconstriction with a shift to the left in the concentration-response curve, this is not significant and is far less marked than the effect
of Mel on NE-induced contraction. For a given
[Ca2+]i mobilization
(
[Ca2+]i) of 0.4 a.u. vasoconstriction
produced by NE was three times greater than that induced by KCl. This
suggests that the potentiating effect of Mel depends on the cellular
mechanism of contraction involved.
An explanation is that a substantial component of the vasoconstrictor response to NE comes from intracellular amplifying mechanisms downstream or independent of [Ca2+]i mobilization such as [Ca2+]i-independent modulation of phosphorylation/dephosphorylation events via diacylglycerol-protein kinase C and other pathways (3, 12, 19, 20, 30). A minor component of the contraction induced by KCl involves NE release from nerve endings (9). It is possible that the slight potentiation of KCl-induced vasoconstriction by Mel involves KCl-induced NE release. A final argument is that at higher levels of [Ca2+]i mobilization, vasoconstriction does not appear to be related to [Ca2+]i mobilization, and at such levels, Mel potentiates NE-induced vasoconstriction but not KCl-induced vasoconstriction. This may be an artifact due to flattening off of the response of [Ca2+]i-fura complex, although maximal fluorescence in the presence of KCl or NE was far less than that produced by ionomycin.
In conclusion, we suggest that Mel potentiates the vasoconstrictor response to NE at some event downstream of [Ca2+]i mobilization, increasing [Ca2+]i sensitivity of constriction. This may be of physiological relevance because the effect occurs at nanomolar Mel concentrations which are attained at the peak of the melatonin circadian rhythm (16).
| |
ACKNOWLEDGEMENTS |
|---|
This work was supported by grants from the French Education, Research and Technology Ministry (EA 3116) and IRIS, Courbevoie, France.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: C. Capdeville-Atkinson, Laboratoire de Pharmacologie Cardiovasculaire, EA 3116, Faculté de Pharmacie, UHP-Nancy 1, 5 rue Albert Lebrun, 54001 Nancy Cedex; IRIS, 6 Place des Pléïades, 92415 Courbevoie Cedex, France (E-mail: capatkin{at}pharma.u-nancy.fr).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 23 May 2000; accepted in final form 12 September 2000.
| |
REFERENCES |
|---|
|
|
|---|
1.
Bosman, H,
Dormehl IC,
Hugo N,
Redelinghuys IF,
and
Theron JJ.
The effect of intravenous administration of melatonin on cardiovascular parameters of the baboon (Papio ursinus).
J Pineal Res
11:
179-181,
1991[ISI][Medline].
2.
Capdeville-Atkinson, C,
Oster L,
Thorin-Trescases N,
Robert A,
Boutinet S,
and
Atkinson J.
Intracellular free Ca2+ and vasoconstriction determined simultaneously in the perfused rat tail artery.
Am J Physiol Cell Physiol
265:
C1689-C1702,
1993
3.
Capdeville-Atkinson, C,
Oster L,
Thorin-Trescases N,
Robert A,
Corman B,
and
Atkinson J.
Effect of chronic ANG I-converting enzyme inhibition on aging processes: V. intracellular calcium-vasoreactivity coupling.
Am J Physiol Regulatory Integrative Comp Physiol
268:
R1394-R1400,
1995
4.
Capsoni, S,
Stankov BM,
and
Fraschini F.
Reduction of regional blood flow by melatonin in young rats.
Neuroreport
6:
1346-1348,
1995[ISI][Medline].
5.
Capsoni, S,
Viswanathan M,
De Oliveira AM,
and
Saavedra JM.
Characterization of melatonin receptors and signal transduction system in rat arteries forming the circle of Willis.
Endocrinology
135:
373-378,
1994[Abstract].
6.
Cunnane, SC,
Manku MS,
Oka M,
and
Horrobin DF.
Enhanced vascular reactivity to various vasoconstrictor agents following pinealectomy in the rat: role of melatonin.
Can J Physiol Pharmacol
58:
287-293,
1980[ISI][Medline].
7.
Doolen, S,
Krause DN,
Dubocovich ML,
and
Duckles SP.
Melatonin mediates two distinct responses in vascular smooth muscle.
Eur J Pharmacol
345:
67-69,
1998[ISI][Medline].
8.
Duckles, SP,
Barrios VE,
Doolen S,
and
Krause DN.
Melatonin receptors potentiate contractile responses to adrenergic nerve stimulation in rat caudal artery.
Proc West Pharmacol Soc
38:
101-102,
1995[Medline].
9.
Fouda, AK,
Kaufmann A,
Thorin E,
Henrion D,
Capdeville-Atkinson C,
and
Atkinson J.
The role of endogenous norepinephrine release in potassium-evoked vasoconstriction of the rat tail artery.
Eur J Pharmacol
205:
63-72,
1991[ISI][Medline].
10.
Geary, GG,
Krause DN,
and
Duckles SP.
Melatonin directly constricts rat cerebral arteries through modulation of potassium channels.
Am J Physiol Heart Circ Physiol
273:
H1530-H1536,
1997
11.
Grynkiewicz, G,
Poenie R,
and
Tsien RY.
A new generation of Ca2+ indicators with greatly improved fluorescence properties.
J Biol Chem
260:
3440-3450,
1985
12.
Karaki, H.
Ca2+ localization and sensitivity in vascular smooth muscle.
Trends Pharmacol Sci
10:
320-325,
1989[Medline].
13.
Konishi, M,
Olson A,
Hollingworth S,
and
Baylor SM.
Myoplasmic binding of fura-2 investigated by steady-state fluorescence and absorbance measurements.
Biophys J
54:
1089-1104,
1988
14.
Krause, DN,
Barrios VE,
and
Duckles SP.
Melatonin receptors mediate potentiation of contractile responses to adrenergic nerve stimulation in rat caudal artery.
Eur J Pharmacol
276:
207-213,
1995[ISI][Medline].
15.
Mahle, CD,
Goggins GD,
Argawal P,
Ryan E,
and
Watson AJ.
Melatonin modulates vascular smooth muscle tone.
J Biol Rythms
12:
690-696,
1997.
16.
Murakami, M,
Greer MA,
Lawy AJ,
Greer SE,
and
McAdams S.
Ontogenesis of pineal thyroxine 5'-deiodinase activity and plasma melatonin concentration in the rat.
Neuroendocrinology
50:
476-480,
1989[ISI][Medline].
17.
Regrigny, O,
Delagrange P,
Scalbert E,
Atkinson J,
and
Lartaud-Idjouadiene I.
Melatonin improves cerebral circulation security margin in rats.
Am J Physiol Heart Circ Physiol
275:
H139-H144,
1998
18.
Reiter, RJ.
Pineal melatonin: cell biology of its synthesis and of its physiological interactions.
Endocr Rev
12:
151-180,
1991[ISI][Medline].
19.
Rembold, CM.
Regulation of contraction and relaxation in arterial smooth muscle.
Hypertension
20:
129-137,
1992
20.
Robert, A,
Tran NPN,
Giummelly P,
Atkinson J,
and
Capdeville-Atkinson C.
Sensitivity of norepinephrine-evoked vasoconstriction to pertussis toxin in old rat.
Am J Physiol Regulatory Integrative Comp Physiol
274:
R1604-R1612,
1998
21.
Satake, N,
Oe H,
Sawada T,
and
Shibata S.
The mode of relaxing action of melatonin in rabbit aorta.
Gen Pharmacol
22:
219-221,
1991a[ISI][Medline].
22.
Satake, N,
Oe H,
and
Shibata S.
Vasorelaxing action of melatonin in rat isolated aorta: possible endothelium-dependent relaxation.
Gen Pharmacol
22:
1127-1133,
1991b[ISI][Medline].
23.
Satake, N,
Shibata S,
and
Takagi T.
The inhibitory action of melatonin on the contractile response to 5-hydroxytryptamine in various isolated vascular smooth muscles.
Gen Pharmacol
17:
553-558,
1986[ISI][Medline].
24.
Scanlon, M,
Williams DA,
and
Fay FS.
A Ca2+ insensitive form of fura-2 associated with polymorphonuclear leukocytes.
J Biol Chem
262:
6308-6312,
1987
25.
Shibata, S,
Satake N,
Takagi T,
and
Usui H.
Vasorelaxing action of melatonin in rabbit basilar artery.
Gen Pharmacol
20:
677-680,
1989[ISI][Medline].
26.
Ting, KN,
Dunn WR,
Davies DJ,
Sugden D,
Delagrange P,
Guardiola-Lemaître B,
Scalbert E,
and
Wilson VG.
Studies on the vasoconstrictor action of melatonin and putative melatonin receptor ligands in the tail artery of juvenile Wistar rats.
Br J Pharmacol
122:
1299-1306,
1997[ISI][Medline].
27.
Tran, NNP,
Spitzbarth E,
Robert A,
Giummelly P,
Atkinson J,
and
Capdeville-Atkinson C.
Nitric oxide lowers calcium sensitivity of tension in the rat tail artery.
J Physiol (Lond)
507:
163-174,
1998
28.
Uto, A,
Arai H,
and
Ogawa Y.
Reassessment of fura-2 and the ratio method for determination of intracellular Ca2+ concentrations.
Cell Calcium
12:
29-37,
1991[ISI][Medline].
29.
Viswanathan, M,
Laitinen JT,
and
Saavedra JM.
Expression of melatonin receptors in arteries involved in thermoregulation.
Proc Natl Acad Sci USA
87:
6200-6203,
1990
30.
Walsh, MP,
Horowitz A,
Clément-Chomienne O,
Andrea JE,
Allen BG,
and
Morgan KG.
Protein kinase C mediation of Ca2+-independent contractions of vascular smooth muscle.
Biochem Cell Biol
74:
485-502,
1996[ISI][Medline].
31.
Weekley, LB.
Effects of melatonin on pulmonary and coronary vessels are exerted through perivascular nerves.
Clin Auton Res
3:
45-47,
1993a[Medline].
This article has been cited by other articles:
![]() |
K. Aoki, D. P. Stephens, K. Zhao, W. A. Kosiba, and J. M. Johnson Modification of cutaneous vasodilator response to heat stress by daytime exogenous melatonin administration Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2006; 291(3): R619 - R624. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |